Related Experiment Video
Updated: Apr 21, 2026
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
Synergistic Inhibition of Angiogenesis and Tumor Progression by CD73 Inhibitor and Menstrual Blood Stem Cell-Derived
Narges Jafarbeik Iravani1, Keivan Majidzadeh-A1, Samaneh Arab2,3
1Genetics Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran.
Objective:
HER2-positive breast cancer (HER2+ BC) remains an aggressive subtype with limited treatment efficacy due to therapeutic resistance and systemic toxicities. CD73, an ectoenzyme producing extracellular adenosine, promotes tumor progression by enhancing angiogenesis, immune evasion, and metastasis. Exosomes derived from menstrual blood mesenchymal stem cells (Exo-Mens) exhibit anti-tumor and anti-angiogenic effects through bioactive cargo delivery. This study investigated the synergistic therapeutic potential of CD73 inhibition (using APCP) combined with Exo-Mens in HER2+ BC, with particular focus on their effects on angiogenesis-related pathways and on the regulation of miR-20a and miR-422a.
Materials And Methods:
SKBR3 HER2+ BC cells were treated with Exo-Mens, APCP, and their combination. Exosomes were isolated and characterized by TEM, DLS, and Western blotting. Cytotoxicity assays determined IC5 0 values and synergy indices. Functional assays (colony formation, scratch migration assay), flow cytometry for apoptosis, and qRT-PCR analysis of pro-angiogenic (HIF-1α, KDR), pro-invasive (NF-κB, MMP9), and microRNAs (miR-20a, miR-422a) were performed.
Results:
APCP showed higher cytotoxic potency (IC5 0 = 12.41 µg/mL) than Exo-Mens (IC5 0 = 61.84 µg/mL). Combination therapy demonstrated strong synergy (combination index < 1), significantly reducing colony formation (10.41% vs. 100% in controls), and cell migration (26.13% wound closure vs. 100% control). Both treatments downregulated angiogenesis factors (HIF-1α, KDR), while invasion markers (NF-κB, MMP9) showed treatment-specific responses. Notably, miR-422a was significantly upregulated across treatments, with the highest fold-change in the combination (3.05 ± 0.05), whereas miR-20a showed only modest changes. Combination therapy also enhanced apoptosis (viable cells reduced to 46.2% vs. 89.1% control).
Conclusion:
The combination of APCP and Exo-Mens demonstrated synergistic anti-tumor effects in HER2+ BC cells by targeting pathways related to angiogenesis, proliferation, and apoptosis. In this context, the upregulation of miR-422a suggests a potential tumor-suppressive role, warranting further investigation.
Insights
Combining CD73 inhibition (APCP) with menstrual blood exosomes (Exo-Mens) shows synergistic anti-tumor effects in HER2-positive breast cancer. This novel combination therapy targets angiogenesis and promotes apoptosis, offering a promising new treatment strategy.
Area of Science:
- Oncology
- Cancer Biology
- Biotechnology
Background:
- HER2-positive breast cancer (HER2+ BC) is an aggressive subtype with poor treatment outcomes due to resistance and toxicity.
- CD73 promotes tumor progression via angiogenesis, immune evasion, and metastasis.
- Menstrual blood mesenchymal stem cell-derived exosomes (Exo-Mens) possess anti-tumor and anti-angiogenic properties.
Purpose of the Study:
- To investigate the synergistic therapeutic potential of combining CD73 inhibition (APCP) with Exo-Mens in HER2+ BC.
- To evaluate the effects on angiogenesis-related pathways and the regulation of specific microRNAs (miR-20a and miR-422a).
Main Methods:
- SKBR3 HER2+ BC cells were treated with Exo-Mens, APCP, and their combination.
- Characterization of exosomes, cytotoxicity assays, synergy analysis, colony formation, migration assays, apoptosis analysis, and qRT-PCR for key genes and microRNAs were performed.
Main Results:
- Combination therapy exhibited strong synergy (combination index < 1), significantly reducing colony formation and cell migration.
- Both treatments downregulated angiogenesis factors (HIF-1α, KDR); combination therapy enhanced apoptosis and significantly upregulated miR-422a.
- APCP demonstrated higher cytotoxic potency than Exo-Mens individually.
Conclusions:
- The combination of APCP and Exo-Mens shows synergistic anti-tumor effects in HER2+ BC by targeting angiogenesis, proliferation, and apoptosis pathways.
- Upregulation of miR-422a by the combination therapy suggests a potential tumor-suppressive role requiring further investigation.
